COLISTIMETHATE FOR INJECTION, USP 150 MG
COLISTIN (COLISTIMETHATE SODIUM) : 150 MG · DIN 02403544 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is COLISTIMETHATE FOR INJECTION, USP?
COLISTIMETHATE FOR INJECTION, USP 150 MG contains COLISTIN (COLISTIMETHATE SODIUM) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02403544, held by FRESENIUS KABI CANADA LTD, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 17-Dec-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is COLISTIMETHATE FOR INJECTION, USP used for?
Acute or chronic infections due to sensitive gram-negative bacilli, particularly P. aeruginosa, A. aerogenes, E. coli, and K. pneumoniae. Not for Proteus or Neisseria.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02403544 |
|---|---|
| Brand name | COLISTIMETHATE FOR INJECTION, USP |
| Generic / active ingredient | COLISTIN (COLISTIMETHATE SODIUM) : 150 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 150 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | J01XB01 COLISTIN |
| AHFS class | 08:12.28.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Dec-2024 |
| Original market date | 2014-06-05 00:00:00 |
How is it administered?
Average dose: 2.5 mg/kg/day in 2-4 divided doses. Max 5 mg/kg/day for normal renal function. Administer IV (direct or infusion) or IM. Reduce dose in renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Powder: 15°C to 30°C. Reconstituted solution: 15°C to 30°C for up to 7 days. Infusion solutions: Use within 24 hours.
How is it supplied?
Vials containing sodium colistimethate equivalent to 150 mg colistin base activity.
Contraindications
Contraindicated in patients with a history of sensitivity to the drug.
Warnings and precautions
Maximum dose 5 mg/kg/day. May cause transient neurological disturbances (paresthesia, dizziness); do not drive. Overdose can cause renal insufficiency, muscle weakness, and apnea.
What can be used instead?
Other Canadian products sharing ATC code J01XB01 COLISTIN. 4 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COLISTIMETHATE FOR INJECTION U.S.P. | 150 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02244849 |
| COLISTIMETHATE FOR INJECTION USP | 150 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02546639 |
| COLY-MYCIN M | 150 MG | POWDER FOR SOLUTION | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00476420 |
Who else supplies COLISTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COLISTIN appears in 20 registered pack listings across 3 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.